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Abstract
Background: Colorado tick fever (CTF) is an acute systemic febrile illness caused by the CTF 
virus (CTFV). The last national summary of CTF cases in the United States included cases 
reported through 2001. This study summarizes national surveillance data for CTF from 2002 
through 2012 and examines trends in the epidemiology and testing of identified CTF cases.
Methods: Because CTF is not nationally notifiable, we identified CTF cases through solicited 
reports from state health departments and diagnostic laboratory records. For all cases, we collected 
data on age, sex, county of residence, travel history, symptom onset date, laboratory testing, and 
clinical outcome. Poisson regression was used to examine trends over time in case counts, and 
simple linear regression and logistic regression were used to examine trends in case 
characteristics.
Results: From 2002 through 2012, 75 CTF cases were identified with a median of five cases per 
year (range 3–14). Forty-seven (63%) cases occurred in males and 49 (65%) occurred in people 
aged ≥ 40 years. The majority (80%) of cases had onset of illness during May through July. Cases 
occurred in residents of 14 states but the infections were acquired in six western states. Wyoming 
had the highest annual incidence of CTF among residents (3.4 cases per million population), 
followed by Montana (1.5 per million), and Utah (0.5 per million). Over the 11 years, there was an 
increase in the proportion of cases diagnosed by RT-PCR testing and in the proportion of cases 
among travelers to another state.
Conclusions: CTF cases continue to occur annually among residents and visitors to the western 
United States. Public health prevention messages about decreasing tick exposure should be 
targeted to residents and travelers who will spend time outdoors in an endemic region during the 
spring and summer months.
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Introduction
Colorado tick fever (CTF) is an acute systemic febrile illness caused by the CTF virus 
(CTFV), a double-stranded RNA virus in the Coltivirus genus and Reoviridae family. The 
virus is transmitted to humans primarily through the bite of an infected Rocky Mountain 
wood tick, Dermacentor andersoni. D. andersoni is found in the western United States and 
Canada at elevations of 4000–10,000 feet, typically in grassy areas near sage or other brush 
(James et al. 2006, Eisen et al. 2008, Romero and Simonsen 2008). Up to 90% of patients 
diagnosed with CTF recall a specific tick exposure preceding their illness onset 
(Goodpasture et al. 1978, Brackney et al. 2010).
The incubation period for CTF is usually 3–4 days (range, 1–14 days). Symptoms can 
include fever, headache, myalgia, and fatigue and can persist for several weeks in some 
patients (Goodpasture et al. 1978). Leukopenia is also commonly noted. CTFV infection 
occasionally results in more severe clinical manifestations, including meningitis, 
encephalitis, and bleeding disorders. Although fatalities are rare, death has been reported in 
three children who developed bleeding disorders following CTFV infections (Spruance and 
Bailey 1973, Centers for Disease Control and Prevention 1972, Goodpasture et al. 1978).
In 2012, CTFV testing was performed at a limited number of facilities in the United States, 
including the Centers for Disease Control and Prevention (CDC), the Montana Public Health 
Laboratory, and Focus Diagnostics. Prior to 2012, testing had been available at several 
additional state health departments (e.g., Utah). The diagnosis of CTF can be made by virus 
isolation, RT-PCR, or antibody testing (Lambert et al. 2007, Basile 2010).
Although CTF is not a nationally notifiable condition, as of 2012 it was reportable in six 
states (Arizona, Montana, New Mexico, Oregon, Utah, and Wyoming). Of the additional six 
states where CTF has historically been identified, it was not reportable in four states 
(California, Colorado, Idaho, and Nevada). Two states (South Dakota and Washington) had 
arboviral infections as reportable conditions, but CTF was not specifically listed.
The last national summary of CTF cases in the United States included cases reported 
between 1987 and 2001 (Marfin and Campbell 2005). This study summarizes national 
surveillance data for CTF from 2002 through 2012 and examines trends in the epidemiology 
and testing of identified CTF cases.
Materials and Methods
We defined a confirmed CTF case as a patient with CTFV isolated in viral culture, CTFV 
RNA detected by RT-PCR, or a four-fold or more rise in CTFV-specific quantitative 
immunoglobulin G (IgG) or neutralizing antibody titers between acute- and convalescent-
phase specimens. We defined a probable case as a patient with anti-CTFV IgM antibodies in 
serum. We identified cases through soliciting reports from state health department and 
laboratory testing performed at the CDC Arbovirus Diagnostic Laboratory from 2002 
through 2012. State health departments of the 12 states where CTF has been identified 
historically were contacted actively to solicit additional cases not reported previously.
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For all confirmed and probable cases, we collected data on age, sex, county of residence, 
travel history, symptom onset date, laboratory testing, and clinical outcome. Data were 
analyzed using SAS statistical software (v. 9.2, SAS Institute, Cary, NC); county of 
residence was mapped using ArcMap, (version 10, ESRI, Redlands, CA). Categorical 
variables were described as counts and proportions, and continuous variables were described 
by median and range. Poisson regression was used to examine trends over time in case 
counts, and simple linear regression and logistic regression were used to examine trends in 
case characteristics. State- and county-specific incidence rates were calculated using 2010 
US Census Bureau data.
Results
A total of 95 possible CTF cases were identified from 2002 through 2012. Of these, 75 
(79%) were classified as confirmed (n = 65) or probable (n = 10) cases. Of the 20 possible 
cases that did not meet the confirmed or probable case definition, 11 had anti-CTFV IgG or 
neutralizing antibodies in a single serum sample, seven had no available laboratory test 
results, and two had no laboratory testing performed. The remainder of this report will focus 
on the confirmed and probable CTF cases.
From 2002 through 2012, a median of five CTF cases (range, 3–14) were identified per year 
(Fig. 1). Forty-seven (63%) case-patients were male (Table 1). Median age was 46 years 
(range, 2–89) and 49 (65%) cases occurred among people aged ≥ 40 years. Month of illness 
onset ranged from March through August, with 60 (80%) case-patients having their illness 
onset during May—July (Fig. 2). Of the 42 case-patients with hospitalization status reported, 
13 (31%) were hospitalized during the course of their illness. There were no significant 
trends over the 11-year time period in the number of cases reported per year, the sex or age 
distribution of cases, hospitalization rates, or seasonality.
From 2002 through 2012, the average annual incidence of reported cases was 0.02 per 
million population (range, 0.01–0.05). Case-patients were residents of 14 states (Fig. 3). 
Wyoming had the most cases (n = 21) identified among their residents, which might have 
been partially due to enhanced diagnosis and surveillance conducted in Sublette County 
during 2009. Five additional states had more than one case identified among their residents: 
Montana (16 cases), Utah(14), Oregon (7), Colorado (7), and Idaho (2) (Table 1). Wyoming 
had the highest annual incidence of reported CTF among residents (3.4 cases per million 
population), followed by Montana (1.5 per million) and Utah (0.5 per million). All other 
states had a reported annual incidence ≤ 0.2 cases per million population. The six states 
where CTF is a notifiable condition accounted for 60 (80%) of all reported CTF cases. 
Sublette County, Wyoming, had the highest number of reported cases (n = 16) and average 
annual incidence among residents (142 cases per million population) (Table 2). Six (38%) of 
the cases from Sublette County were reported in 2009 during their enhanced surveillance 
efforts; three additional CTF cases were identified that year among travelers to Sublette 
County. No other county reported more than six cases total during the 11 years.
On the basis of known history of travel and exposure, all case-patients were likely infected 
with CTFV in an endemic area in one of six states (Colorado, Idaho, Montana, Oregon, 
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Utah, or Wyoming). Nine counties in Wyoming, Montana, Utah, and Oregon were the likely 
exposure location for at least 46 (61%) cases. Eleven (15%) case-patients were likely 
exposed during travel to another state, including four travelers from states where local 
transmission of CTFV has not been reported (Iowa, Missouri, Nebraska, Pennsylvania). The 
proportion of travel-associated cases increased during the study period, with only one (2%) 
of 44 cases from 2002 through 2007 identified in travelers to other states compared with 10 
(32%) of 31 from 2008 through 2012 (p < 0.01).
Diagnostic testing
Diagnostic testing for the 75 cases was performed at the CDC (40 cases), a state health 
department laboratory (26 cases), and/or a commercial laboratory (11 cases); two cases had 
samples tested at more than one location. For 72 (96%) cases, the diagnosis was confirmed 
by using one method, including a four-fold or more rise in IgG or neutralizing antibody titers 
for 33 (44%) cases, RT-PCR for 21 (28%) cases, IgM antibody testing for 10 (13%) cases, 
and viral culture for 8 (11%) cases. Diagnosis was made by more than one method for three 
(4%) cases; specifically, one case was confirmed by a four-fold or more rise in titers and RT-
PCR, one by RT-PCR and viral culture, and one by IgM antibody testing and viral culture. 
The proportion of cases that were laboratory-confirmed by a four-fold or more rise in 
antibody titers decreased from 77% (27/35) during 2002–2005 to 18% (7/40) during 2006–
2012 (p < 0.01). This finding corresponded with the use of CTFV RT-PCR, which became 
routinely available in 2006, with 58% (23/40) of cases confirmed by RT-PCR during 2006–
2012. There was no significant trend in the proportion of cases diagnosed by viral culture or 
IgM antibody testing during the study period.
All of the 23 serum specimens tested by RT-PCR were collected ≤ 15 days after illness onset 
and all were positive for CTFV RNA (Table 3). One (7%) of 14 specimens collected < 14 
days after illness onset was positive for CTFV neutralizing antibodies compared to 18 (90%) 
of 20 specimens collected ≥ 14 days after onset of illness (p < 0.01). Similarly, two (20%) of 
10 specimens collected within 2 weeks after illness onset were positive for CTFV IgG 
antibodies versus eight (89%) of nine collected at ≥ 14 days (p < 0.01). Data on the timing 
of specimens obtained for viral culture and IgM antibody testing were not available.
Fatal case report
A single fatality was identified. The patient was an adult male > 80 years of age who lived in 
an urban county of an endemic state and had no recent travel. He had multiple underlying 
medical conditions (i.e., chronic obstructive pulmonary disease, chronic renal insufficiency, 
atrial fibrillation, congestive heart failure, and coronary artery disease) and was admitted to 
the hospital for 10 days in August for fever and diarrhea. During hospitalization, the patient 
was noted to be leukopenic (1.9 × 103 leukocytes/μL). The patient tested positive for CTFV 
infection by both viral culture and IgM and IgG antibody testing. He also had an equivocal 
result for hantavirus IgM antibodies and was positive for hantavirus IgG antibodies. At 6 
days after discharge, he was readmitted for continued weakness, abdominal pain, and 
diarrhea. He was hypoxic and had bilateral pleural effusions. Sixteen days after being 
readmitted, he died from progressive respiratory failure with disseminated intravascular 
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coagulation and renal failure. Autopsy findings were consistent with acute exacerbation of 
interstitial pneumonia.
Discussion
From 2002 through 2012, the number of CTF cases reported in the United States remained 
relatively low, with less than 15 cases per year. We found no trends over the 11-year period 
in the incidence, demographic characteristics, or geographic distribution of cases. However, 
there were increases in the number of cases recognized among travelers and in the 
proportion of cases diagnosed by RT-PCR testing.
From 1987 through 2001, a median of 55 CTF cases per year was reported in the United 
States (Marfin and Campbell 2005). However, that number declined consistently over the 
15-year period, with a median of 80 cases annually from 1987 through 1994 (range, 55–96) 
and 18 cases per year from 1995 through 2001 (range, 7–54). This report shows that the drop 
in the number of reported cases has continued, with a median of only five cases per year 
from 2002 through 2012. This decline is likely due, at least in part, to changes in testing and 
reporting practices. For example, Colorado historically reported the largest number of CTF 
cases (Tsai 1991, Marfin and Campbell 2005). However, CTF was not a notifiable condition 
in Colorado from 1997 through 2013, and during 2002 through 2012, Wyoming, Montana, 
Utah, and Oregon each reported more CTF cases than Colorado. In 2009, Wyoming 
instituted active enhanced CTF surveillance in Sublette County by contacting healthcare 
providers in the county and offering testing for all suspected CTF cases. This resulted in the 
identification of nine CTF cases, the highest number of cases reported to the CDC from one 
state or county since 1998 (Geissler et al. 2014). Of these nine cases, six were residents of 
the county; these represented 29% of all cases reported from Wyoming during the 11-year 
time period. The remaining three CTF cases were among travelers to the county. These 
results suggest that CTF is underdiagnosed and underreported, even in states where it is a 
notifiable condition and among travelers. Therefore, it is likely that CTF is causing more 
illness and morbidity among persons living in or visiting endemic areas than is currently 
recognized.
The seasonality of CTF cases in this report was similar to previous reports, with the majority 
of cases occurring during May through July (Spruance and Bailey 1973, Goodpasture et al. 
1978, Brackney et al. 2010). In studies from the 1970s, most CTF cases were identified 
among males aged 20–39 years (Spruance and Bailey 1973, Goodpasture et al. 1978). By 
contrast, we found that 64% of reported cases from 2002 through 2012 occurred in males, 
but 65% of all cases were in adults aged ≥ 40 years. These findings were similar to those 
during 1995–2003 from Montana, Utah, and Wyoming, where 69% of the cases were male 
and the highest incidence was in people aged ≥ 50 years (Brackney et al. 2010). Potential 
explanations for these trends in the demographic characteristics of CTF cases over the last 
several decades may include changes in care-seeking behavior, testing, or surveillance 
practices or true differences in who is being exposed due to increases in recreational 
activities among persons of all ages and sexes.
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The case-fatality ratio for CTF is quite low, with rare fatal cases identified only in children 
(Centers for Disease Control and Prevention 1972, Spruance and Bailey 1973, Goodpasture 
et al. 1978). To our knowledge, this report contains the first fatality in an adult patient 
infected with CTFV. However, the elderly patient had significant underlying medical 
conditions, and his respiratory failure was attributed to interstitial pneumonia. Although 
CTFV has been associated previously with one case of atypical pneumonitis (Byrd et al. 
1997, Goodpasture et al. 1978), it is unclear what role the virus infection played in his death.
Travel to an endemic area is a known risk factor for developing CTF (Drevets 1957, 
Midoneck et al. 1994). We found that the proportion of case-patients who became infected 
while traveling to an endemic area in another state increased during 2002–2012. This could 
be attributed to increased disease awareness and testing in certain locations (e.g., Sublette 
County in 2009) or increased recreation in the Rocky Mountain region during the study 
period (Brackney et al. 2010). Given these findings, prevention messages should be targeted 
to people who are visiting endemic areas and engaging in behaviors that might place them in 
contact with ticks, like hiking or camping.
Healthcare providers should consider CTF in the differential diagnosis of febrile illness 
among persons who have spent time in areas of the Rocky Mountain region, where they may 
have come in contact with D. andersoni. They should obtain samples and order appropriate 
laboratory tests based on the timing of the specimen collection. The findings of this study 
and others suggest that molecular testing (e.g., RT-PCR) is most useful on samples obtained 
during the first 2 weeks after illness onset when antibody testing is often negative (Calisher 
et al. 1985, Basile 2010). Samples obtained after the second or third week of the illness are 
more likely to test positive for CTFV IgG or neutralizing antibodies. Due to the prolonged 
viremia and sequestration of CTFV in red blood cells, healthcare providers should also 
advise patients with CTF against donating blood for 6 months following their illness onset to 
prevent cases of transfusion-associated transmission of CTF (Hughes et al. 1974, Centers for 
Disease Control and Prevention 1975, Philip et al. 1975). Finally, healthcare providers 
should report patients who test positive for CTF to their state health department, where 
applicable.
These data are subject to several limitations. The number of CTF cases identified likely 
underestimates of the true number of CTF cases because patients may not present for 
medical care and healthcare providers may not consider CTFV infection in the differential 
diagnosis or obtain appropriate diagnostic testing. In addition, we only identified cases 
tested at CDC or reported to CDC by state health departments. Because CTF is not 
reportable in all states where the disease occurs, case finding and reporting are not 
standardized across jurisdictions and some cases diagnosed by testing at a commercial 
laboratory could have been missed. We had limited information regarding the patients’ 
symptoms and could not include a clinically compatible illness as part of the case definition. 
As a result, we used conservative criteria for laboratory evidence of recent CTFV infection 
by excluding reported cases with a single elevated IgG or neutralizing antibody titer. 
However, given the expected low seroprevalence and lack of viruses in the United States that 
would result in cross-reactive antibodies, these criteria likely led to underestimating the 
number of acute disease cases. Finally, states and counties of likely exposure were based on 
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reported travel histories and may not always accurately reflect the location at which the 
case-patient became infected with CTFV.
Conclusions
CTF remains a cause of febrile illness among persons living in and traveling to areas of the 
Rocky Mountain region where D. andersoni is found. Public health prevention messages 
(e.g., reducing exposure to ticks through use of personal protective measures such as use of 
repellents and long pants) should be targeted to persons who are spending time outdoors in 
an endemic region during March through August, particularly during the peak CTFV 
transmission season of May through July.
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FIG. 1. 
Number of confirmed and probable Colorado tick fever cases by year, 2002–2012.
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FIG. 2. 
Number of confirmed and probable Colorado tick fever (CTF) cases by month of illness 
onset. Month of illness onset was known for 70 (93%) of 75 confirmed and probable CTF 
cases.
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FIG. 3. 
Approximate geographic distribution of D. andersoni ticks and counties of residence for 
confirmed and probable Colorado tick fever (CTF) virus disease cases, United States, 2002–
2012. (*) All cases were acquired in states where local transmission of CTF virus has been 
reported previously. Two additional cases were reported from Colorado with unknown 
county of residence. (**) Derived from James et al. (2006).
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Table 1.
Characteristics of Confirmedand Probable CTF Cases: United States, 2002–2012
Characteristic
CTF cases (n = 75)
No. (%)
Male 47 (63)
Age (years)
 0–19 11 (15)
 20–39 13 (17)
 40–59 30 (40)
 ≥ 60 19 (25)
 Unknown 2 (3)
State of residence
 Wyominga 21 (28)
 Montanaa 16 (21)
 Utaha 14 (19)
 Oregona 7 (9)
 Colorado 7 (9)
 Idaho 2 (3)
 Otherb 8 (11)
aColorado tick fever (CTF) was specifically listed as reportable disease condition during the study period.
bOne case each was identified among residents of Arizona,a California, Iowa, Missouri, Nebraska, New Mexico,a Pennsylvania, and Washington. 
Each of these cases was associated with travel to a state listed in the table.
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Table 2.
Number of Confirmed and Probable CTF Cases and Average Annual Incidence per Million Population by 
County of Residence for Counties with More Than One Case:United States, 2002–2012
CTF cases
County and state of residence No. Rate per million
Sublette, Wyominga 16 141.9
Missoula, Montana 6 5.0
Salt Lake, Utah 5 0.4
Big Horn, Montana 4 28.3
Wasatch, Utah 4 15.5
Ravalli, Montana 4 9.0
Deschutes, Oregon 3 1.7
Davis, Utah 3 0.9
Carbon, Wyoming 2 11.4
Multnomah, Oregon 2 0.3
Albany, Wyoming 2 5.0
Boulder, Colorado 2 0.6
aActive surveillance for Colorado tick fever (CTF) occurred in Sublette County, Wyoming, in 2009.
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